Bivamax
Bivamax Uses, Dosage, Side Effects, Mechanism of Action, How Long Does it Take to Work? Bivamax is a brand name. Its generic name is Bivalirudin.
Introduction
Bivamax is an anticoagulant (blood thinner) medication used to prevent and treat certain types of blood clots including deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a synthetic peptide derived from hirudin, a natural anticoagulant found in leeches. Bivamax is used to prevent the formation of clots in the arteries and veins of catheterized patients or those undergoing certain heart procedures such as coronary angioplasty and stenting.Uses For
Bivamax is used to reduce the risk of stroke, chest pain, and heart attack for patients with acute coronary syndrome (ACS) and percutaneous coronary interventions (PCI). Additionally, Bivamax is used for the prevention of blood clots in patients with acute coronary syndrome and other conditions.Mechanism of Action
Bivamax works by inhibiting the action of thrombin, an enzyme responsible for converting fibrinogen into fibrin, which are integral parts of the clotting process. Bivamax binds to thrombin and prevents the conversion of fibrinogen into fibrin, thereby reducing the formation of clots.How Long Does It Take To Work?
Bivamax generally works within minutes of administration, but the full effects may not be seen for up to 24 hours.Absorption, Route of Elimination, Dosage, Administration
Bivamax is administered intravenously (IV) and has an oral bioavailability of less than 1%. The elimination half-life of bivalirudin is approximately 3 hours. The recommended dosage of bivalirudin is 0.75mg/kg of body weight administered as a bolus followed by a continuous infusion of 1.75 mg/kg/hour.Side Effect, Toxicity, Precaution
The most commonly reported side effects of bivalirudin are bleeding, fever, rash, and nausea. Bivamax can potentially cause serious and life-threatening bleeding complications. Therefore, it is important to monitor any signs and symptoms of bleeding and report them to a healthcare provider immediately. The drug should be used with caution in patients with a history of bleeding and in those with low platelet counts, coagulation disorders or a high risk of bleeding.Interaction, Disease Interaction, Drug Interaction, Food Interactions
Bivamax may interact with other medications including anticoagulants, antiplatelet medications, antibiotics, and antiplatelet medications. The drug can also interact with certain laboratory tests. It is important to inform your healthcare provider of any medications or supplements you are taking before starting bivalirudin therapy. Additionally, it is also important to inform your healthcare provider of any known allergies or medical conditions such as liver or kidney disease.Pregnancy Use, Lactation Use
Bivamax is classified as a Pregnancy Category C drug. It is not recommended for use in pregnant women unless the potential benefits outweigh the possible risks. Bivamax is excreted in breast milk. Therefore, it is not recommended for use in breastfeeding women unless the potential benefits outweigh the potential risks.Acute Overdose
The symptoms of an acute overdose of bivalirudin may include severe bleeding, dizziness, weakness, seizures, and coma. Treatment of an overdose may include intravenous fluids, hemodialysis, and blood transfusions if necessary.Contraindication, Use Direction, Storage Condition
Bivamax is contraindicated in patients with active internal bleeding. Bivamax should be administered intravenously and the infusion rate should be monitored closely for any signs of bleeding. The medication should be stored at room temperature and protected from light and moisture.Volume of Distribution, Half Life, Clearance
Bivamax has a volume of distribution of 35-45L. The elimination half-life is approximately 3 hours. The clearance of bivalirudin is approximately 5mL/min.Here you find in details version of Bivamax
Some Frequently Asked Questions About Bivamax
https://www.medicinesfaq.com/brand/bivamax,
,
,
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:59173,
http://www.genome.jp/dbget-bin/www_bget?drug:D03136,
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16129704,
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507415,
https://www.chemspider.com/Chemical-Structure.10482069.html,
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50248103,
https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=60819,
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=59173,
https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL2103749,
http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000542,
http://www.pharmgkb.org/drug/PA10032,
http://www.rxlist.com/cgi/generic/angiomax.htm,
https://www.drugs.com/cdi/bivalirudin.html,
https://en.wikipedia.org/wiki/Bivalirudin,